Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated efficacy of 31%. RV144 secondary immune correlate analysis demonstrated that the combination of low plasma anti-HIV-1 Env IgA antibodies and high levels of antibody-dependent cellular cytotoxicity (ADCC) inversely correlate with infec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bonsignori, Mattia, Pollara, Justin, Moody, M. Anthony, Alpert, Michael D., Chen, Xi, Hwang, Kwan-Ki, Gilbert, Peter B., Huang, Ying, Gurley, Thaddeus C., Kozink, Daniel M., Marshall, Dawn J., Whitesides, John F., Tsao, Chun-Yen, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Kim, Jerome H., Michael, Nelson L., Tomaras, Georgia D., Montefiori, David C., Lewis, George K., DeVico, Anthony, Evans, David T., Ferrari, Guido, Liao, Hua-Xin, Haynes, Barton F.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2012
Matèries:
Vaccines and Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3486290/
https://ncbi.nlm.nih.gov/pubmed/22896626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01023-12
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars